Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$60.77
-1.8%
$52.92
$44.12
$78.48
$5.86B1.711.83 million shs1.67 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$18.36
-2.6%
$13.35
$1.33
$24.28
$5.71B0.666.69 million shs5.24 million shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$5.92
+0.3%
$4.84
$1.99
$6.55
$1.53B0.652.07 million shs2.63 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$91.03
-8.9%
$71.79
$23.30
$105.47
$5.67B2.111.53 million shs2.60 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+3.01%+9.83%+19.39%+24.53%+18.67%
Erasca, Inc. stock logo
ERAS
Erasca
+2.06%+3.06%+57.48%+10.49%+1,265.94%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-2.32%-7.67%+17.53%+104.15%+113.07%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+0.70%+1.60%+44.37%+99.38%+162.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$60.77
-1.8%
$52.92
$44.12
$78.48
$5.86B1.711.83 million shs1.67 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$18.36
-2.6%
$13.35
$1.33
$24.28
$5.71B0.666.69 million shs5.24 million shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$5.92
+0.3%
$4.84
$1.99
$6.55
$1.53B0.652.07 million shs2.63 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$91.03
-8.9%
$71.79
$23.30
$105.47
$5.67B2.111.53 million shs2.60 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+3.01%+9.83%+19.39%+24.53%+18.67%
Erasca, Inc. stock logo
ERAS
Erasca
+2.06%+3.06%+57.48%+10.49%+1,265.94%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-2.32%-7.67%+17.53%+104.15%+113.07%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+0.70%+1.60%+44.37%+99.38%+162.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.58
Moderate Buy$67.7811.53% Upside
Erasca, Inc. stock logo
ERAS
Erasca
2.60
Moderate Buy$20.119.54% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.20
Hold$5.50-7.09% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$84.30-7.39% Downside

Current Analyst Ratings Breakdown

Latest MRVI, ERAS, CRSP, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingMarket Outperform$80.00
7/6/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
DowngradeOutperformIn-Line$102.00
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/12/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Set Price Target$80.00
(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,669.88N/AN/A$20.17 per share3.01
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.05 per shareN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$185.74M8.23$0.41 per share14.43$1.46 per share4.05
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M15.05N/AN/A$7.84 per share11.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$130.77M-$0.71N/AN/AN/A-51.07%-17.87%-9.08%8/10/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest MRVI, ERAS, CRSP, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.1966N/AN/AN/A$7.11 millionN/A
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.50N/AN/AN/A$114.54 millionN/A
5/11/2026Q1 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1150-$0.60-$0.4850-$0.60N/AN/A
5/7/2026Q1 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.05$0.01+$0.06-$0.02$53.00 million$65.84 million
5/4/2026Q1 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.32
17.97
17.96
Erasca, Inc. stock logo
ERAS
Erasca
N/A
9.52
9.52
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.72
5.91
4.96
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Erasca, Inc. stock logo
ERAS
Erasca
14.20%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.49%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.45 million92.50 millionOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120310.98 million266.83 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610258.19 million251.76 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$60.77 -1.12 (-1.81%)
Closing price 04:00 PM Eastern
Extended Trading
$60.14 -0.64 (-1.04%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Erasca stock logo

Erasca NASDAQ:ERAS

$18.36 -0.49 (-2.60%)
Closing price 04:00 PM Eastern
Extended Trading
$18.66 +0.30 (+1.64%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$5.92 +0.02 (+0.34%)
Closing price 04:00 PM Eastern
Extended Trading
$5.90 -0.02 (-0.34%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$91.03 -8.90 (-8.91%)
Closing price 04:00 PM Eastern
Extended Trading
$90.02 -1.02 (-1.12%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.